Blitz Bureau
Establishment Of A Clinical Research Platform For Infectious And Neglected Rare Diseases
With the aim to aid lower socio-economic strata, and provide affordable diagnostics and treatment, HUDCO along with Office of Principal Scientific Adviser to the Govt of India and NCBS-TIFR, in collaboration with TIGS, decided to establish a comprehensive clinical research platform within the Bengaluru Life Science Cluster (BLiSC) to work on infectious disease and neglected rare diseases, as part of a large scale translational health research using genomics and advanced cell biology. HUDCO under their CSR initiatives, is supporting the project and the grant is set to fuel large-scale translational health research, leveraging genomics and advanced cell biology to tackle some of the most challenging health issues of our time. This state-of-the-art facility is focusing on translational research and collaborative services, supporting product development for government agencies, industry, and startups., driving high-impact Research, Design, and Development (RD&D) with production potential.
Nestled within the vibrant Bengaluru Life Science Cluster (BLiSc), the new facility will not only focus on in-house translational research but also serve as a collaborative hub for product development. This effort is particularly targeted at the lower socio-economic strata, who often struggle to afford the high costs associated with diagnostics and treatment.
The National Centre for Biological Sciences (NCBS) and TIFR is ensuring the highest standards of clinical applications, and that facility is designed to address the pressing need of advanced healthcare infrastructure, which was acutely felt during the pandemic, underscoring the importance of application-oriented Research, Design, and Development (R&D) with production potential.
A Catalyst for Innovation and Early-Stage Research:
The HUDCO funding has provided a crucial impetus for early-stage research and innovation. NCBS-TIFR is confident that the benefits of this project will be far-reaching, not only in advancing scientific understanding but also in improving health outcomes for large patient populations through clinicians and industry partnerships.
As NCBS-TIFR continues to pave the way for innovative healthcare solutions, this new clinical research platform stands as a testament to their commitment to excellence in research and development. The future of health innovation in India looks promising, with significant strides being made towards addressing some of the most pressing health challenges of our time.
What to Expect from the New Facility:
The facility promises to be a game-changer, focusing on a range of critical research areas:
1. Genome Sequencing and Analysis:
– Identifying genetic correlates of rare diseases.
– Discovering potential vaccine candidates effective against all known variants of viral pathogens.
2. Vaccine and Therapeutic Development:
– Developing both DNA and RNA-based vaccine and therapeutic candidates.
3. Animal Experiments and Pre-clinical Trials:
– Conducting rigorous pre-clinical trials to ensure the efficacy and safety of new treatments.
4. Comprehensive Immunological Assays:
– Determining and analyzing antibody titers across the spectrum, including IgG, IgM, B and T cell assays, and viral protection assays.
5. GMP Facility:
– Producing lead molecules for preclinical and clinical trials.
6. Statistical and Mathematical Modelling Expertise:
– Designing and analyzing data from all pre-clinical and clinical trials with world-class expertise.
